Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 92.20 |
---|---|
High | 93.70 |
Low | 92.20 |
Bid | -- |
Offer | -- |
Previous close | 93.70 |
Average volume | 921.60 |
---|---|
Shares outstanding | 2.53bn |
Free float | 2.53bn |
P/E (TTM) | 20.43 |
Market cap | 246.49bn USD |
EPS (TTM) | 4.77 USD |
Annual div (ADY) | 3.07 EUR |
---|---|
Annual div yield (ADY) | 3.30% |
Div ex-date | Sep 16 2024 |
Div pay-date | Oct 07 2024 |
Next div ex-date | Dec 16 2024 |
Next div pay-date | Jan 08 2025 |
Data delayed at least 15 minutes, as of Nov 21 2024 16:36 GMT.
More ▼
Press releases
- Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
- Merck Announces First-Quarter 2025 Dividend
- Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
- Merck to Participate in the Jefferies London Healthcare Conference
- Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
- KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
- Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Merck to Participate in the UBS Global Healthcare Conference
More ▼